LivaNova PLC
NASDAQ: LIVN
NYSE
NYSE
Healthcare
Medical Devices
Global Rank
#5250
Country Rank
#163
Market Cap
2.53 B
Price
46.31
Change (%)
0.78%
Volume
775,311
LivaNova PLC's latest marketcap:
2.53 B
As of 06/10/2025, LivaNova PLC's market capitalization has reached $2.53 B. According to our data, LivaNova PLC is the 5250th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2.53 B |
| Revenue (ttm) | 1.28 B |
| Net Income (ttm) | -222,145,000 |
| Shares Out | 54.53 M |
| EPS (ttm) | -4.09 |
| Forward PE | 12.62 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/30/2025 |
Market Cap Chart
Data Updated: 06/10/2025
LivaNova PLC's yearly market capitalization.
LivaNova PLC has seen its market value drop from $2.9 B to $2.53 B since 2015, representing a total decrease of 12.91% and an annual compound decline rate (CAGR) of 1.45%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/10/2025 | $2.53 B | -0.37% |
| 12/31/2024 | $2.51 B | -9.78% |
| 12/29/2023 | $2.79 B | -6.24% |
| 12/30/2022 | $2.97 B | -36.12% |
| 12/31/2021 | $4.65 B | 44.63% |
| 12/31/2020 | $3.22 B | -11.87% |
| 12/31/2019 | $3.65 B | -18.02% |
| 12/31/2018 | $4.45 B | 15.57% |
| 12/29/2017 | $3.85 B | 75.67% |
| 12/30/2016 | $2.19 B | -24.35% |
Company Profile
About LivaNova PLC
LivaNova PLC is a global medical technology company specializing in innovative therapies for neurological and cardiac conditions. Founded in 2015 and headquartered in London, UK, the company serves healthcare professionals and institutions worldwide.
Business Segments
- Cardiopulmonary: Provides advanced products such as heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing, and surgical accessories.
- Neuromodulation: Offers the VNS Therapy System, an implantable device for treating drug-resistant epilepsy and difficult-to-treat depression through vagus nerve stimulation.
Key Offerings
- Cardiopulmonary solutions for surgical and critical care.
- Neuromodulation therapies for neurological disorders.
Customer Base
LivaNova serves:
- Perfusionists, neurologists, and neurosurgeons.
- Hospitals and healthcare providers.
Distribution Network
The company markets its products through direct sales teams, agents, and independent distributors.
Frequently Asked Questions
-
What is LivaNova PLC's (LIVN) current market cap?As of 06/10/2025, LivaNova PLC (including the parent company, if applicable) has an estimated market capitalization of $2.53 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does LivaNova PLC (LIVN) rank globally by market cap?LivaNova PLC global market capitalization ranking is approximately 5250 as of 06/10/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.